<p>成功駕馭股市需要耐心和長期的視角。關鍵在於堅持一致的計劃，並定期向退休賬户做出貢獻，讓複利的力量隨着時間的推移發揮其魔力。</p>
<p>然而，尋找潛在的多倍收益股票無疑具有吸引力。那些擁有顛覆性創新的公司，其股票可能正處於快速增長的邊緣，能夠為股東帶來改變生活的回報，這讓人着迷。</p>
<p><strong>Recursion Pharmaceuticals</strong>（RXRX -0.98%）是一家臨牀階段的生物科技公司，可能具備這樣的潛力。該公司利用人工智能（AI）進行藥物發現，承諾將徹底改變醫學。讓我們探討一下購買該股票是否最終能幫助你成為百萬富翁。</p>
<h2>AI 驅動的生物科技</h2>
<p>Recursion 迅速確立了自己在 AI 驅動生物科技領域的領導地位。該公司的 BioHive-2 超級計算機，採用 <strong>Nvidia</strong> AI 芯片，是全球最強大的加速計算系統之一。</p>
<p>通過先進的機器學習技術，BioHive-2 分析大量生物數據，以識別藥物靶點，包括與疾病相關的蛋白質和基因。Recursion 的操作系統（OS）評估數百萬種化合物，以識別潛在的藥物候選者，同時預測藥物分子的特性和最佳患者羣體，以增強藥物設計。</p>
<p>這些努力使得對各種疾病的治療研究得以加速，同時與傳統方法相比降低了成本。</p>
<p>Recursion 今年的一項重大進展是與另一家專注於基於 AI 藥物發現的生物科技公司 Exscientia 的合併。Exscientia 在先進化學設計方法方面的專業知識與 Recursion 的生物驅動方法相輔相成。這一結合創造了一個垂直整合的平台，使公司在根本上更強大。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>有前景的治療候選藥物管線</h2>
<p>好消息是，Recursion 的技術已經取得了令人鼓舞的成果，擁有一條強大的藥物候選管線，現在還包括 Exscientia 的遺留項目。</p>
<p>其中最有前景的候選藥物之一是 REC-994，它可能成為治療症狀性腦血管畸形（CCM）的首個口服療法，這是一種目前沒有任何批准治療的腦出血疾病。</p>
<p>REC-617 也顯示出令人鼓舞的結果，最近的 1 期中期研究表明，在治療晚期實體瘤方面患者反應積極且耐受性良好。公司認為該藥物具有 “最佳同類” 潛力，這是使 Recursion 成為投資者引人注目的機會的幾個原因之一。</p>
<p>展望 2025 年，市場將密切關注臨牀結果和監管更新，作為 Recursion 股票的催化劑：</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA"/></p>
<p>來源：Recursion Pharmaceuticals。</p>
<h2>謹慎的理由</h2>
<p>看起來至少有一個 Recursion Pharmaceuticals 的候選藥物最終可能獲得批准，作為一種新療法，使公司在未來十年內轉變為一個商業可持續的運營。</p>
<p>但要為該股票做出更為樂觀的投資案例，作為一種能夠多倍增值的投資，將是一個更具挑戰性的命題。這可能需要 Recursion 開發出一種能夠在多個年度內產生數十億美元銷售額的重磅藥物。</p>
<p>現實是，Recursion 距離將藥物推向市場還有數年時間。目前，該公司僅通過合作里程碑付款和研究資助產生有限收入，同時面臨顯著更高的運營費用。華爾街分析師預計在可預見的未來將繼續出現財務虧損，預計每股收益（EPS）將從今年預計的虧損 1.54 美元惡化至 2025 年的 1.65 美元。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>指標</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024（估計）</strong></td>
<td><strong>2025（估計）</strong></td>
</tr>
<tr>
<td>收入（百萬美元）</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>收入變化（同比）</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>每股收益（EPS）</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS 變化（同比）</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>數據來源：Yahoo Finance。同比 = 年比年。</p>
<p>雖然市場可以基於長期增長前景忽視缺乏盈利能力，但這種動態可能會使股票承壓。Recursion 的股票從 52 周高點下跌了約 55%，任何監管方面的挫折都可能使股票進一步下跌。</p>
<p>另一個考慮因素是高度競爭的行業格局。像 <strong>Merck</strong>、<strong>AstraZeneca</strong> 和 <strong>Pfizer</strong> 等主要生物科技和製藥公司，越來越多地在其研發過程中使用人工智能。這種廣泛的採用引發了關於 Recursion 是否能夠在該領域保持技術優勢的質疑。</p>
<h2>最後思考</h2>
<p>儘管 Recursion Pharmaceuticals 提供了引人注目的可能性，但我認為在對其產品批准路徑沒有更好可見性的情況下，現在購買該股票還為時尚早。與此同時，2025 年將是該公司提供更多關於其長期潛力的關鍵一年。你可能想將其保持在你的關注名單上。</p>

RXRX

<p>Recursion Pharmaceuticals 是一家利用人工智能進行藥物發現的臨牀階段生物技術公司，具有顯著的增長潛力。其 BioHive-2 超級計算機分析生物數據以識別藥物靶點，與 Exscientia 的合併增強了其能力。像 REC-994 和 REC-617 這樣的有前景的藥物候選者顯示出潛力，但公司面臨挑戰，包括財務虧損和來自大型公司的競爭。分析師預測持續虧損，儘管股票具有潛力，但在沒有更清晰的產品批准時間表之前，投資可能為時尚早。2025 年將是 Recursion 未來的關鍵年</p>

<p>Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.</p>
<div class="lb-trans"><p>成功駕馭股市需要耐心和長期的視角。關鍵在於堅持一致的計劃，並定期向退休賬户做出貢獻，讓複利的力量隨着時間的推移發揮其魔力。</p>
</div><p>Nevertheless, there's an undeniable allure in searching for potential multibagger stocks. Something is captivating about companies with disruptive innovations, whose stocks could be on the cusp of rapid growth and capable of delivering life-changing returns to shareholders.</p>
<div class="lb-trans"><p>然而，尋找潛在的多倍收益股票無疑具有吸引力。那些擁有顛覆性創新的公司，其股票可能正處於快速增長的邊緣，能夠為股東帶來改變生活的回報，這讓人着迷。</p>
</div><p><strong>Recursion Pharmaceuticals</strong>(RXRX -0.98%) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to revolutionize medicine. Let's explore whether buying the stock could eventually help you become a millionaire.</p>
<div class="lb-trans"><p><strong>Recursion Pharmaceuticals</strong>（RXRX -0.98%）是一家臨牀階段的生物科技公司，可能具備這樣的潛力。該公司利用人工智能（AI）進行藥物發現，承諾將徹底改變醫學。讓我們探討一下購買該股票是否最終能幫助你成為百萬富翁。</p>
</div><h2>AI-powered biotech</h2>
<div class="lb-trans"><h2>AI 驅動的生物科技</h2>
</div><p>Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by <strong>Nvidia</strong> AI chips, is one of the world's most powerful accelerated computing systems.</p>
<div class="lb-trans"><p>Recursion 迅速確立了自己在 AI 驅動生物科技領域的領導地位。該公司的 BioHive-2 超級計算機，採用 <strong>Nvidia</strong> AI 芯片，是全球最強大的加速計算系統之一。</p>
</div><p>Through advanced machine learning techniques, BioHive-2 analyzes vast amounts of biological data to identify drug targets, including proteins and genes involved in disease. Recursion's operating system (OS) evaluates millions of compounds to identify potential drug candidates, while also predicting drug molecule properties and optimal patient populations to enhance drug design.</p>
<div class="lb-trans"><p>通過先進的機器學習技術，BioHive-2 分析大量生物數據，以識別藥物靶點，包括與疾病相關的蛋白質和基因。Recursion 的操作系統（OS）評估數百萬種化合物，以識別潛在的藥物候選者，同時預測藥物分子的特性和最佳患者羣體，以增強藥物設計。</p>
</div><p>These efforts allow accelerated research on treatments across a wide range of conditions, while reducing costs compared to traditional methods.</p>
<div class="lb-trans"><p>這些努力使得對各種疾病的治療研究得以加速，同時與傳統方法相比降低了成本。</p>
</div><p>A major development for Recursion this year was its merger with Exscientia, another biotech company focused on AI-based drug discovery. Exscientia's expertise in advanced methods of chemical design complements Recursion's biology-driven approach. This combination has created a vertically integrated platform, resulting in a fundamentally stronger company.</p>
<div class="lb-trans"><p>Recursion 今年的一項重大進展是與另一家專注於基於 AI 藥物發現的生物科技公司 Exscientia 的合併。Exscientia 在先進化學設計方法方面的專業知識與 Recursion 的生物驅動方法相輔相成。這一結合創造了一個垂直整合的平台，使公司在根本上更強大。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvcmVjdXNpb24tcGhhcm1hLWFpLXBvd2VyZWQtYmlvdGVjaC1zdG9jay5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801422%2Frecusion-pharma-ai-powered-biotech-stock.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>A promising pipeline of therapeutic candidates</h2>
<div class="lb-trans"><h2>有前景的治療候選藥物管線</h2>
</div><p>The good news is that Recursion's technology has already yielded promising results, with a robust pipeline of drug candidates that now incorporates Exscientia's legacy programs.</p>
<div class="lb-trans"><p>好消息是，Recursion 的技術已經取得了令人鼓舞的成果，擁有一條強大的藥物候選管線，現在還包括 Exscientia 的遺留項目。</p>
</div><p>One of the most promising prospects is REC-994, which could become the first oral therapy for treating symptomatic cerebral cavernous malformation (CCM), a brain hemorrhaging condition that currently lacks any approved treatments.</p>
<div class="lb-trans"><p>其中最有前景的候選藥物之一是 REC-994，它可能成為治療症狀性腦血管畸形（CCM）的首個口服療法，這是一種目前沒有任何批准治療的腦出血疾病。</p>
</div><p>REC-617 has also shown encouraging results, with a recent phase 1 interim study demonstrating positive patient responses and good tolerability in treating advanced solid tumors. The company believes this drug has &#34;best in class&#34; potential, one of several reasons that make Recursion an intriguing opportunity for investors.</p>
<div class="lb-trans"><p>REC-617 也顯示出令人鼓舞的結果，最近的 1 期中期研究表明，在治療晚期實體瘤方面患者反應積極且耐受性良好。公司認為該藥物具有 “最佳同類” 潛力，這是使 Recursion 成為投資者引人注目的機會的幾個原因之一。</p>
</div><p>Looking ahead to 2025, the market will be closely following clinical readouts and regulatory updates as catalysts for Recursion stock:</p>
<div class="lb-trans"><p>展望 2025 年，市場將密切關注臨牀結果和監管更新，作為 Recursion 股票的催化劑：</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDE0MjIvbGFyZ2UtcGlwZWxpbmUtcmVjdXJzaW9uLXN0b2NrLWJ1bGxpc2gtb3V0bG9vay0yMDI1LnBuZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801422%2Flarge-pipeline-recursion-stock-bullish-outlook-2025.png&amp;op=resize&amp;w=700"/></p>
<p>Source: Recursion Pharmaceuticals.</p>
<div class="lb-trans"><p>來源：Recursion Pharmaceuticals。</p>
</div><h2>Reasons for caution</h2>
<div class="lb-trans"><h2>謹慎的理由</h2>
</div><p>It seems likely that at least one of Recursion Pharmaceuticals' candidates could eventually gain approval as a novel therapy, transforming the company into a commercially sustainable operation over the next decade.</p>
<div class="lb-trans"><p>看起來至少有一個 Recursion Pharmaceuticals 的候選藥物最終可能獲得批准，作為一種新療法，使公司在未來十年內轉變為一個商業可持續的運營。</p>
</div><p>But making a much more bullish case for the stock, as an investment to multiply many times over, would be a significantly more challenging proposition. It would likely require Recursion to develop a blockbuster drug capable of generating billions of dollars in sales across multiple years.</p>
<div class="lb-trans"><p>但要為該股票做出更為樂觀的投資案例，作為一種能夠多倍增值的投資，將是一個更具挑戰性的命題。這可能需要 Recursion 開發出一種能夠在多個年度內產生數十億美元銷售額的重磅藥物。</p>
</div><p>The reality is that Recursion remains years away from bringing a drug to market. Currently, the company generates only limited revenue through partnership milestone payments and research grants, while facing substantially higher operating expenses. Wall Street analysts project continued financial losses for the foreseeable future, with negative earnings per share (EPS) expected to worsen from a projected loss of $1.54 this year to $1.65 in 2025.</p>
<div class="lb-trans"><p>現實是，Recursion 距離將藥物推向市場還有數年時間。目前，該公司僅通過合作里程碑付款和研究資助產生有限收入，同時面臨顯著更高的運營費用。華爾街分析師預計在可預見的未來將繼續出現財務虧損，預計每股收益（EPS）將從今年預計的虧損 1.54 美元惡化至 2025 年的 1.65 美元。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metric</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024 (Estimate)</strong></td>
<td><strong>2025 (Estimate)</strong></td>
</tr>
<tr>
<td>Revenue (in millions)</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>Revenue change (YOY)</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>Earnings per share (EPS)</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS change (YOY)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>指標</strong></td>
<td><strong>2023</strong></td>
<td><strong>2024（估計）</strong></td>
<td><strong>2025（估計）</strong></td>
</tr>
<tr>
<td>收入（百萬美元）</td>
<td>$44.6</td>
<td>$70.0</td>
<td>$76.0</td>
</tr>
<tr>
<td>收入變化（同比）</td>
<td>12%</td>
<td>57%</td>
<td>9%</td>
</tr>
<tr>
<td>每股收益（EPS）</td>
<td>($1.58)</td>
<td>($1.54)</td>
<td>($1.65)</td>
</tr>
<tr>
<td>EPS 變化（同比）</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>Data source: Yahoo Finance. YOY = year over year.</p>
<div class="lb-trans"><p>數據來源：Yahoo Finance。同比 = 年比年。</p>
</div><p>While the market can overlook a lack of profitability based on longer-term growth prospects, the dynamic may keep the stock under pressure. Shares of Recursion are down approximately 55% from their 52-week high, and any sort of regulatory setback could send the stock even lower.</p>
<div class="lb-trans"><p>雖然市場可以基於長期增長前景忽視缺乏盈利能力，但這種動態可能會使股票承壓。Recursion 的股票從 52 周高點下跌了約 55%，任何監管方面的挫折都可能使股票進一步下跌。</p>
</div><p>Another consideration is the highly competitive industry landscape. Major biotech and pharmaceutical companies like <strong>Merck</strong>, <strong>AstraZeneca</strong>, and <strong>Pfizer</strong>, among others, are increasingly using artificial intelligence in their research and development processes. This widespread adoption raises questions about whether Recursion can maintain a technological advantage in the field.</p>
<div class="lb-trans"><p>另一個考慮因素是高度競爭的行業格局。像 <strong>Merck</strong>、<strong>AstraZeneca</strong> 和 <strong>Pfizer</strong> 等主要生物科技和製藥公司，越來越多地在其研發過程中使用人工智能。這種廣泛的採用引發了關於 Recursion 是否能夠在該領域保持技術優勢的質疑。</p>
</div><h2>Final thoughts</h2>
<div class="lb-trans"><h2>最後思考</h2>
</div><p>Although Recursion Pharmaceuticals offers compelling possibilities, I believe that without better visibility into its product approval pathway, it's just too early to buy this stock with conviction. In the meantime, 2025 will be a crucial year for the company to offer more clarity on its long-term potential. You may want to keep this one on your radar.</p>
<div class="lb-trans"><p>儘管 Recursion Pharmaceuticals 提供了引人注目的可能性，但我認為在對其產品批准路徑沒有更好可見性的情況下，現在購買該股票還為時尚早。與此同時，2025 年將是該公司提供更多關於其長期潛力的關鍵一年。你可能想將其保持在你的關注名單上。</p>
</div>

Recursion Pharmaceuticals 的股票能否成為百萬富翁製造者？